I fully agree with your view.
The upward trend in research and development expenses started in the last quarter. First quarter $ 4.257 mln, second quarter $ 4.273 mln, third quarter $ 4.667 mln and last quarter $ 7.090 mln.This increase was,so is stated in the last report, due to research services provided to the Genomics Center and "increased expenses incurred in the Company's regulated gene therapy program, including manufacturing PROCESS development and other ADVANCED preclinical development costs". This sentence is mostly identical to that in the third quarter, with an exception for the words, put, by me, in capitals, which were this time added. Gives this some indication, that we can expect more, and interesting, news in the coming months?
Also a milestone-payment for the osteoporosis signal transduction inhibitor program?
Martin |
